Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis

Omar Khan, Rana Zabad, Christina Caon, Marina Zvartau-Hind, Alexandros Tselis, Robert Lisak

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The past decade has seen unprecedented advances in the development of disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS), a disease that has a worldwide prevalence of two million patients. Four agents with the ability to modulate the immune system are now being widely used for RRMS. Of these, three are forms of interferon (IFN)-β [IFNβ-1b and two preparations of IFNβ-1a (Avonex®1 and Rebif®)], and one is a polypeptide of four amino acids (glatiramer acetate) with a unique mechanism of action. The administration regimens for the IFNβ-1a products differ, with Avonex® being given as 30μg intramuscularly once a week and Rebif® being given as 22 or 44μg subcutaneously three times a week. It appears safe to predict that both forms of IFNβ and glatiramer acetate will remain standard treatments for MS for years to come. However, with four therapeutic options available for RRMS, selecting a single therapy is often difficult and necessitates comparisons of the agents, which can be contentious. All four agents have shown superiority over placebo in pivotal phase III trials. Three recent prospective comparative studies have indicated that IFNβ-1b, Rebif® and glatiramer acetate may be more optimal choices than Avonex® for patients with RRMS. In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients.

Original languageEnglish (US)
Pages (from-to)563-578
Number of pages16
JournalCNS Drugs
Volume16
Issue number8
DOIs
StatePublished - Jan 1 2002

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Interferons
Therapeutics
Immune System
Placebos
Interferon beta-1a
Prospective Studies
Amino Acids
Peptides
Pharmaceutical Preparations
Glatiramer Acetate

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. / Khan, Omar; Zabad, Rana; Caon, Christina; Zvartau-Hind, Marina; Tselis, Alexandros; Lisak, Robert.

In: CNS Drugs, Vol. 16, No. 8, 01.01.2002, p. 563-578.

Research output: Contribution to journalReview article

Khan, Omar ; Zabad, Rana ; Caon, Christina ; Zvartau-Hind, Marina ; Tselis, Alexandros ; Lisak, Robert. / Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. In: CNS Drugs. 2002 ; Vol. 16, No. 8. pp. 563-578.
@article{1b4bdeef628f4b1bbfdff4a40e21d468,
title = "Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis",
abstract = "The past decade has seen unprecedented advances in the development of disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS), a disease that has a worldwide prevalence of two million patients. Four agents with the ability to modulate the immune system are now being widely used for RRMS. Of these, three are forms of interferon (IFN)-β [IFNβ-1b and two preparations of IFNβ-1a (Avonex{\circledR}1 and Rebif{\circledR})], and one is a polypeptide of four amino acids (glatiramer acetate) with a unique mechanism of action. The administration regimens for the IFNβ-1a products differ, with Avonex{\circledR} being given as 30μg intramuscularly once a week and Rebif{\circledR} being given as 22 or 44μg subcutaneously three times a week. It appears safe to predict that both forms of IFNβ and glatiramer acetate will remain standard treatments for MS for years to come. However, with four therapeutic options available for RRMS, selecting a single therapy is often difficult and necessitates comparisons of the agents, which can be contentious. All four agents have shown superiority over placebo in pivotal phase III trials. Three recent prospective comparative studies have indicated that IFNβ-1b, Rebif{\circledR} and glatiramer acetate may be more optimal choices than Avonex{\circledR} for patients with RRMS. In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients.",
author = "Omar Khan and Rana Zabad and Christina Caon and Marina Zvartau-Hind and Alexandros Tselis and Robert Lisak",
year = "2002",
month = "1",
day = "1",
doi = "10.2165/00023210-200216080-00005",
language = "English (US)",
volume = "16",
pages = "563--578",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis

AU - Khan, Omar

AU - Zabad, Rana

AU - Caon, Christina

AU - Zvartau-Hind, Marina

AU - Tselis, Alexandros

AU - Lisak, Robert

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The past decade has seen unprecedented advances in the development of disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS), a disease that has a worldwide prevalence of two million patients. Four agents with the ability to modulate the immune system are now being widely used for RRMS. Of these, three are forms of interferon (IFN)-β [IFNβ-1b and two preparations of IFNβ-1a (Avonex®1 and Rebif®)], and one is a polypeptide of four amino acids (glatiramer acetate) with a unique mechanism of action. The administration regimens for the IFNβ-1a products differ, with Avonex® being given as 30μg intramuscularly once a week and Rebif® being given as 22 or 44μg subcutaneously three times a week. It appears safe to predict that both forms of IFNβ and glatiramer acetate will remain standard treatments for MS for years to come. However, with four therapeutic options available for RRMS, selecting a single therapy is often difficult and necessitates comparisons of the agents, which can be contentious. All four agents have shown superiority over placebo in pivotal phase III trials. Three recent prospective comparative studies have indicated that IFNβ-1b, Rebif® and glatiramer acetate may be more optimal choices than Avonex® for patients with RRMS. In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients.

AB - The past decade has seen unprecedented advances in the development of disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS), a disease that has a worldwide prevalence of two million patients. Four agents with the ability to modulate the immune system are now being widely used for RRMS. Of these, three are forms of interferon (IFN)-β [IFNβ-1b and two preparations of IFNβ-1a (Avonex®1 and Rebif®)], and one is a polypeptide of four amino acids (glatiramer acetate) with a unique mechanism of action. The administration regimens for the IFNβ-1a products differ, with Avonex® being given as 30μg intramuscularly once a week and Rebif® being given as 22 or 44μg subcutaneously three times a week. It appears safe to predict that both forms of IFNβ and glatiramer acetate will remain standard treatments for MS for years to come. However, with four therapeutic options available for RRMS, selecting a single therapy is often difficult and necessitates comparisons of the agents, which can be contentious. All four agents have shown superiority over placebo in pivotal phase III trials. Three recent prospective comparative studies have indicated that IFNβ-1b, Rebif® and glatiramer acetate may be more optimal choices than Avonex® for patients with RRMS. In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients.

UR - http://www.scopus.com/inward/record.url?scp=0036316169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036316169&partnerID=8YFLogxK

U2 - 10.2165/00023210-200216080-00005

DO - 10.2165/00023210-200216080-00005

M3 - Review article

C2 - 12096936

AN - SCOPUS:0036316169

VL - 16

SP - 563

EP - 578

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 8

ER -